Abbott has announced that Apollo Hospitals has successfully treated a coronary artery disease patient with the company’s revolutionary ABSORB drug eluting Bioresorbable Vascular Scaffold (BVS), thus becoming the first hospital in Chennai to use this innovative product. Abbott’s ABSORB is a groundbreaking device currently in clinical trials that is designed to restore blood flow by opening a clogged vessel and providing support while it heals.
Once the vessel can remain open without the extra support, the bioresorbable scaffold is designed to be slowly metabolised and eventually dissolve and disappear from the body. Apollo Hospitals is the first in Chennai and one of the few hospitals in India to enroll a patient into the ABSORB EXTEND trial, a worldwide trial of up to 1,000 patients at 100 centers in Europe, Asia Pacific, Canada and Latin America. To date, approximately 200 patients have been implanted with the device, and data have been presented on patients at various time intervals,including 30 patients out to four years. Dr Pratap Reddy, Chairman, Apollo Hospitals said, “Introduction of this new device – Abbott ABSORB is part of our endeavor to bring in cutting edge technology to prevent and give the best possible outcome for coronary artery disease.
I commend Abbott for developing this innovative product, Dr Mathew Samuel Kalarickal father of angioplasty for bringing this product first time to Chennai and Dr Sai Satish for bringing in a patient centric approach to cardiology.